InvestorsHub Logo
Post# of 252491
Next 10
Followers 56
Posts 1150
Boards Moderated 0
Alias Born 11/12/2005

Re: DewDiligence post# 90094

Wednesday, 02/03/2010 10:56:05 PM

Wednesday, February 03, 2010 10:56:05 PM

Post# of 252491
Dendreon released the total number of possible patients, a rate limiting manufacturing range, and a graph showing how other first-in-class biologics ramped in their first couple of years of sales. They have explicity NOT released pricing data, except to say it would be comparable to other biologics with similar life extension.

There are people who can make educated guesses (some of us more educated than others because we know the right questions to ask), but they haven't done anything almost every other biotech has done.

Unless otherwise indicated, this is the personal viewpoint of David
Miller and not necessarily that of Biotech Stock Research, LLC.
We're on Twitter at BiotechStockRsr

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.